Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy

American Journal of Nephrology

Volumn 35, Issue 4, 2012, Pages 312-320

  Zhang, Qingxian ^a   Shi, Su Fang ^a   Zhu, Li ^a   Lv, Ji Cheng ^a   Liu, Li Jun ^a   Chen, Yu Qing ^a   Zhang, Hong ^a,b   Wang, Hai Yan ^a  

^a BEIJING HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Cytoskeleton; IgA nephropathy; Podocyte; Proteinuria; Tacrolimus

Indexed keywords

CALCINEURIN; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PUROMYCIN AMINONUCLEOSIDE; RITUXIMAB; STEROID; SYNAPTOPODIN; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; COLPITIS MYCOTICA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY PARENCHYMA; MALE; NAUSEA; NEPHROTOXICITY; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEINURIA; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINITIS;

ACTINS; ADOLESCENT; ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; CALCINEURIN; CELLS, CULTURED; CYTOSKELETON; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MIDDLE AGED; PODOCYTES; PREDNISONE; PROTEINURIA; REMISSION INDUCTION; SYNAPTOPHYSIN; TACROLIMUS; YOUNG ADULT;

EID: 84858979606     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000337175     Document Type: Article

References (25)

1. Reich HN, Troyanov S, Scholey JW, et al: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177-3183. (Pubitemid 350223978)
2. Li PK, Leung CB, Chow KM, et al: Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751-760.
3. Barratt J, Feehally J: Treatment of IgA nephropathy. Kidney Int 2006; 69: 1934-1938. (Pubitemid 43924255)
4. Lv J, Zhang H, Chen Y, et al: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009; 53: 26-32.
5. Manno C, Torres DD, Rossini M, et al: Randomized controlled clinical trial of corticosteroids plus ACE inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-3701.
6. Tang S, Leung JC, Chan LY, et al: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812. (Pubitemid 43323137)
7. Lai KN, Lai FM, Ho CP, et al: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180. (Pubitemid 16025306)
8. Duncan N, Dhaygude A, Owen J, et al: Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004; 19: 3062-3067. (Pubitemid 40057629)
9. Loeffler K, Gowrishankar M, Yiu V: Tacrolimus therapy in pediatric patients with treatment- resistant nephrotic syndrome. Pediatr Nephrol 2004; 19: 281-287. (Pubitemid 38313011)
10. Faul C, Donnelly M, Merscher-Gomez S, et al: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938.
11. Mathieson PW: Proteinuria and immunity - an overstated relationship? N Engl J Med 2008; 359: 2492-2494.
12. Zheng CX, Chen ZH, Zeng CH, et al: Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 2008; 74: 596-612.
13. Ma YC, Zuo L, Chen JH, et al: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944. (Pubitemid 44484685)
14. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
15. Cattran DC, Coppo R, Cook HT, et al: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
16. Haas M: Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842. (Pubitemid 27251835)
17. Saleem MA, O'Hare MJ, Reiser J, et al: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638. (Pubitemid 34183927)
18. Schweda F, Liebl R, Riegger GA, et al: Tacrolimus treatment for steroid- and cyclosporin- resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant 1997; 12: 2433-2435. (Pubitemid 27474637)
19. Li X, Li H, Ye H, et al: Tacrolimus therapy in adults with steroid- and cyclophosphamideresistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009; 54: 51-58.
20. Roberti I, Vyas S: Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 2010; 25: 1117-1124.
21. Shankland SJ: The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147. (Pubitemid 43882099)
22. Patrakka J, Tryggvason K: New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009; 5: 463-468.
23. Lemley KV, Lafayette RA, Safai M, et al: Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485. (Pubitemid 34304509)
24. Hishiki T, Shirato I, Takahashi Y, et al: Podocyte injury predicts prognosis in patients with IgA nephropathy using a small amount of renal biopsy tissue. Kidney Blood Press Res 2001; 24: 99-104. (Pubitemid 32642062)
25. Wang Y, Jarad G, Tripathi P, et al: Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol 2010; 21: 1657-1666.